Rather than producing medicines through batch-wise, step-by-step processes, CONTINUUS Pharmaceuticals offers a breakthrough Integrated Continuous Manufacturing (ICM) technology for small molecule pharmaceuticals. The synthesis of the active ingredient and the final dosage form are integrated into a seamless process. This novel method will allow “on-demand” manufacturing of pharmaceuticals with significant advantages in production lead time, quality, and costs.
CONTINUUS Pharmaceuticals is a spin-out company of the $65 M collaboration between MIT and Novartis on continuous manufacturing, We design, build, and run our manufacturing processes directly at the client site. This novel business strategy provides our pharmaceutical and generic clients with an exceptional, ”one-shop solution” for their entire development and manufacturing cycle. Our success is based on the establishment of long term partnerships with our clients.
June 16, 2015
CONTINUUS Pharmaceuticals Presents at 2015 Annual BIO International Convention
April 23, 2015
CONTINUUS to present at the NSF/NIH Bio Innovation Zone during the 2015 BIO International Convention, June 15-18
April 15, 2015
CONTINUUS Pharmaceuticals featured in World Pharmaceutical Frontiers